Departments of Medicine/Oncology
and Cancer Center, McGill University; Leader, Drug Discovery Program, Montreal
Centre for Experimental Therapeutics in Cancer
Lady Davis Institute
for Medical Research
3755, Chemin Cote-Ste-Catherine
Montreal, Quebec, Canada H3T 1E2
Tel. 514-340-8260/8222 Ext. 3438/3432
My research career has included a breadth of interdisciplinary
studies spanning the fields of cancer biology, drug resistance, cancer models,
and novel therapeutics. Recently my laboratory has begun to branch out further
into the areas of genomic and proteomic applied to cancer progression and cancer
targeting. My laboratory has contributed to several novel findings to understand
the biology of cancer, including (1) discovery of a novel member of the TRIP
gene family of transcription factors called RBT1, and which encode for an oncoprotein
involved in the regulation of cell cycle (NIH Gene bank: AF192529 and AF317202),
(2) identification of molecular switches by which aberrant expression of growth
factor receptors of the ErbB family induces tumor invasion of distant sites,
and (3) discovery of novel interactors of the cell-cell communication proteins
called connexins, which we reported to be deregulated in cancer. My work has
been published in peer-review cancer journals, and was recently summarized in
an invited review for the journal "Drug Resistance Updates" and a
book chapter on cancer therapeutics (see list of selected publications).
In addition to basic and applied research, my laboratory has
established a national and international expertise in screening for novel
therapeutics in a variety of relevant non-invasive and invasive in vivo cancer
models established in this laboratory. Over 15 pharmaceutical companies from
Canada and abroad have used our expertise to develop novel cancer therapeutics.
· Characterization of the molecular switches by which
growth factor receptor signaling promotes the disorganization of the extracellular
matrix, activation of local host stroma, and neovascularization.
· Characterization of in vitro and in vivo function(s) of RBT1, a novel
cancer associated gene discovered in this laboratory.
· Understanding the mechanisms by which HCV and HBV oncoproteins and
the associated inflammatory processes promote carcinogenesis.
· Development of novel cancer targets and molecules we identified by
genomic and biochemical approaches, and design of inhibitors for therapeutic